Results 31 to 40 of about 2,870,340 (221)
Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review
Journal of Ophthalmic & Vision Research, 2021 Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non ...
Francisco Barroso +2 more
doaj +1 more source
Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
Frontiers in Pharmacology, 2020 PDE4 inhibitors can suppress a variety of inflammatory cell functions that contribute to their anti-inflammatory actions in respiratory diseases like chronic obstructive pulmonary disease (COPD) and asthma.
J. Phillips
semanticscholar +1 more source
Pharmacotherapy of erectile dysfunction: Current standards
Indian Journal of Urology, 2006 Pharmacotherapy is currently the therapeutic option of choice for erectile dysfunction. Comprising mainly intracavernosal injection therapy using alprostadil or alprostadil combined with phentolamine and/or papaverine and oral phosphodiesterase-5 ...
Kew-Kim Chew
doaj +1 more source
Inhibitors of phosphodiesterase as cancer therapeutics.
European Journal of Medicinal Chemistry, 2018 Phosphodiesterases (PDEs) are a class of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) which is involved in many physiological processes including visual transduction, cell proliferation and differentiation, cell-cycle regulation, gene expression, inflammation, apoptosis, and metabolic function ...
Ting Peng +7 more
semanticscholar +3 more sources
Phosphonic acid-containing inhibitors of tyrosyl-DNA phosphodiesterase 1
Frontiers in Chemistry, 2022 Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs stalled type I topoisomerase (TOP1)-DNA complexes by hydrolyzing the phosphodiester bond between the TOP1 Y723 residue and the 3′-phosphate of its DNA substrate.
Xue Zhi Zhao +6 more
doaj +1 more source
Molecules, 2021 A series of deoxycholic acid (DCA) amides containing benzyl ether groups on the steroid core were tested against the tyrosyl-DNA phosphodiesterase 1 (TDP1) and 2 (TDP2) enzymes.
Oksana V. Salomatina +9 more
doaj +1 more source
Expert Opinion on Investigational Drugs, 2017 Introduction: Phosphodiesterase (PDE) inhibitors improve signaling pathways in brain circuits by increasing intracellular cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP).
J. Prickaerts +2 more
semanticscholar +1 more source
Data in Brief, 2019 This paper presents the data on the optimisation and validation of a liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to establish the presence of phosphodiesterase 5 (PDE5) inhibitors and their analogues as adulterants in instant coffee
Ahmad Yusri Mohd Yusop +2 more
doaj +1 more source
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Frontiers in Pharmacology, 2018 Phosphodiesterase-4 (PDE4), mainly present in immune cells, epithelial cells, and brain cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and epithelial integrity. Inhibition of PDE4 is predicted to have diverse effects
Heng Li, Jian-Ping Zuo, Wei Tang
semanticscholar +1 more source
Nature Communications, 2020 Phosphodiesterase-5 (PDE5) inhibitors have been suggested to have an anti-tumor effect and block surgery-induced immunosuppression. Here, the authors show that postdiagnostic use of PDE5 inhibitors is associated with a decreased risk of colorectal ...
Wuqing Huang +3 more
doaj +1 more source